文献速递重症综合管理与镇静镇痛

早期氯胺酮镇静与COVID-19机械通气患者临床及费用结局的关联:一项回顾性队列研究

Use of Early Ketamine Sedation and Association With Clinical and Cost Outcomes Among Mechanically Ventilated Patients With COVID-19: A Retrospective Cohort Study.
PubMed 文献 · Crit Care Explor · 2024-06-21
一句话结论在COVID-19机械通气患者中,早期使用氯胺酮与住院死亡率、总费用、ICU住院时间和通气天数增加相关,但与住院总时间、升压药天数和肾脏替代治疗无关联。

本研究为回顾性队列研究,利用2020年4月至2021年6月间610家医院参与的Premier Healthcare数据库,纳入住院5天内连续机械通气≥2天的成人COVID-19患者。早期氯胺酮定义为插管后2天内开始并持续使用超过1天。在42,954例患者中,1,423例(3.3%)接受了早期氯胺酮。经倾向性评分匹配每组1,390例后,氯胺酮组住院死亡率更高(52.5% vs. 45.9%,风险比1.14[1.06-1.23]),ICU住院时间更长(中位数13 vs. 12天,均值比1.15[1.08-1.23]),通气天数更长(12 vs. 11天,均值比1.19[1.12-1.27]),总住院费用更高(中位数72,481 vs. 65,584美元,均值比1.11[1.05-1.19])。住院总时间、升压药天数和肾脏替代治疗无显著关联。作者指出氯胺酮组体外膜肺氧合和肾脏替代治疗使用率更高,可能存在疾病严重程度混杂,需进一步随机试验。

要点

  • 在42,954例COVID-19机械通气患者中,1,423例(3.3%)接受了早期氯胺酮(插管后2天内开始并持续>1天)。
  • 倾向性评分匹配后,氯胺酮组住院死亡率52.5% vs. 对照组45.9%,风险比1.14(95%CI 1.06-1.23)。
  • 氯胺酮组ICU住院时间中位数13 vs. 12天(均值比1.15[1.08-1.23]),通气天数12 vs. 11天(均值比1.19[1.12-1.27])。
  • 氯胺酮组总住院费用中位数72,481 vs. 65,584美元(均值比1.11[1.05-1.19]),住院总时间、升压药天数和肾脏替代治疗无显著关联。
  • 作者认为可能存在疾病严重程度混杂(氯胺酮组体外膜肺氧合和肾脏替代治疗使用率更高),需进一步随机试验。

适用人群与场景

  • 成人COVID-19患者,住院5天内连续机械通气≥2天。
  • 数据来自2020年4月至2021年6月间610家参与Premier Healthcare数据库的美国医院。

诊断标准与关键阈值

  • 早期氯胺酮暴露:插管后2天内开始使用氯胺酮并持续使用超过1天。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量42,954例,其中1,423例(3.3%)接受早期氯胺酮;倾向性评分匹配后每组1,390例。
  • 主要终点:住院死亡率氯胺酮组52.5% vs. 对照组45.9%,风险比1.14(95%CI 1.06-1.23)。
  • 次要终点:ICU住院时间中位数13 vs. 12天(均值比1.15[1.08-1.23]);通气天数12 vs. 11天(均值比1.19[1.12-1.27]);总住院费用中位数72,481 vs. 65,584美元(均值比1.11[1.05-1.19])。
  • 无显著关联的次要终点:住院总时间17(10-27)vs. 17(9-28)天(均值比1.05[0.99-1.12]);升压药天数4 vs. 4天(均值比1.04[0.95-1.14]);肾脏替代治疗22.9% vs. 21.7%(风险比1.05[0.92-1.21])。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:作者指出可能存在疾病严重程度混杂,因氯胺酮组体外膜肺氧合和肾脏替代治疗使用率更高;需进一步随机试验以更好理解氯胺酮输注在危重症患者管理中的作用。

对床旁实践的改变

  • 作者认为早期氯胺酮可能与更高的住院死亡率、总费用、ICU住院时间和通气天数相关,但与住院总时间、升压药天数和肾脏替代治疗无关联。
  • 作者指出由于氯胺酮组体外膜肺氧合和肾脏替代治疗使用率更高,可能存在疾病严重程度混杂,需进一步随机试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To describe the utilization of early ketamine use among patients mechanically ventilated for COVID-19, and examine associations with in-hospital mortality and other clinical outcomes.

DESIGN: Retrospective cohort study.

SETTING: Six hundred ten hospitals contributing data to the Premier Healthcare Database between April 2020 and June 2021.

PATIENTS: Adults with COVID-19 and greater than or equal to 2 consecutive days of mechanical ventilation within 5 days of hospitalization.

INTERVENTION: The exposures were early ketamine use initiated within 2 days of intubation and continued for greater than 1 day.

MEASUREMENTS: Primary was hospital mortality. Secondary outcomes included length of stay (LOS) in the hospital and ICUs, ventilator days, vasopressor days, renal replacement therapy (RRT), and total hospital cost. The propensity score matching analysis was used to adjust for confounders.

MAIN RESULTS: Among 42,954 patients, 1,423 (3.3%) were exposed to early ketamine use. After propensity score matching including 1,390 patients in each group, recipients of ketamine infusions were associated with higher hospital mortality (52.5% vs. 45.9%, risk ratio: 1.14, [1.06-1.23]), longer median ICU stay (13 vs. 12 d, mean ratio [MR]: 1.15 [1.08-1.23]), and longer ventilator days (12 vs. 11 d, MR: 1.19 [1.12-1.27]). There were no associations for hospital LOS (17 [10-27] vs. 17 [9-28], MR: 1.05 [0.99-1.12]), vasopressor days (4 vs. 4, MR: 1.04 [0.95-1.14]), and RRT (22.9% vs. 21.7%, RR: 1.05 [0.92-1.21]). Total hospital cost was higher (median $72,481 vs. $65,584, MR: 1.11 [1.05-1.19]).

CONCLUSIONS: In a diverse sample of U.S. hospitals, about one in 30 patients mechanically ventilated with COVID-19 received ketamine infusions. Early ketamine may have an association with higher hospital mortality, increased total cost, ICU stay, and ventilator days, but no associations for hospital LOS, vasopressor days, and RRT. However, confounding by the severity of illness might occur due to higher extracorporeal membrane oxygenation and RRT use in the ketamine group. Further randomized trials are needed to better understand the role of ketamine infusions in the management of critically ill patients.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Royce-Nagel G, Jarzebowski M, Wongsripuemtet P, et al. Use of Early Ketamine Sedation and Association With Clinical and Cost Outcomes Among Mechanically Ventilated Patients With COVID-19: A Retrospective Cohort Study. Crit Care Explor. 2024. PMID: 38904975. doi:10.1097/CCE.0000000000001105

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。